EpiVax and CUBRC Secure FDA Contract for Innovative Peptide Research
EpiVax, Inc. and CUBRC, Inc. are excited to announce their collaboration on a newly awarded two-year, $2 million contract from the Office of Generic Drugs (OGD) of the FDA. This initiative focuses on developing standardized controls for T cell assays aimed at assessing the immunogenicity risk of generic drugs to support Abbreviated New Drug Applications (ANDA). This effort is essential in meeting the FDA guidance standards for evaluating novel and existing therapies.
The Importance of Generic Peptide Drugs
Generic peptide drugs play a critical role in enhancing healthcare access. They offer effective treatment options similar to branded versions but at significantly lower prices. The FDA has consistently advocated for the availability of these medicines, balancing accessibility with robust standards that ensure the efficacy and safety of the drugs.
Advancements Through Continued Research
This recent contract reflects a culmination of EpiVax's previous efforts involving FDA contracts focused on immunogenicity risk assessments. Previous research paved the way by employing both in silico and in vitro methods. During the first contract, EpiVax showcased the potential of these methods for analyzing the immunogenicity risks of current generic peptide drugs. They have demonstrated that computational approaches significantly enhance the assessment and management of potential drug impurities.
Developing the What-if Machine
Under a second contract, EpiVax presented the What-if Machine (WhIM)—an innovative algorithm that modifies amino acid sequences of synthetic peptides, identifying various potential impurities. This proactive method helps drug developers understand which impurities may pose significant immunogenicity risks, facilitating more informed decision-making regarding drug development.
Goals of the FDA-Funded Collaboration
In the current research program, EpiVax aims to identify and validate core peptide-sized controls, both positive and negative, needed for supporting generic peptide drug applications. Common peptides in need of thorough assessment include teriparatide, exenatide, liraglutide, and tirzepatide. The integrity of the Peptide Abbreviated New Drug Application (PANDA) process builds upon the previously successful methodologies for identifying potentially immunogenic impurities.
Further Research Publications
EpiVax's accomplishments can be explored further in two significant research articles. These documents delve into immunogenicity risk assessments for synthetic peptide drugs and their impurities, showcasing the scientific rigor behind the current FDA project.
Commitment to Safe and Effective Therapies
Through this FDA-funded research, EpiVax and CUBRC are committed to improving access to safe and effective generic peptide drug products. Their efforts will help establish new industry standards that enhance immunogenicity assessments, ultimately benefiting patient health and the pharmaceutical landscape as a whole.
About EpiVax
EpiVax is recognized as a pioneer in immunogenicity assessment and sequence optimization in peptide therapeutics and biologics. Its collaborations with global partners advance the field of immunogenicity risk assessment, immune modulation, and innovative vaccine design.
About CUBRC
CUBRC is an esteemed independent scientific corporation engaged in various research domains, including medical sciences and data fusion technologies. Their expertise complements EpiVax's capabilities, enhancing the outcomes of collaborative projects.
Frequently Asked Questions
What is the primary goal of the FDA contract awarded to EpiVax and CUBRC?
The contract aims to develop standardized controls for T cell assays that assess the immunogenicity risk of generic drugs to support ANDA applications.
How do generic peptide drugs enhance healthcare access?
They provide affordable alternatives to branded medications, ensuring more patients can access effective treatments.
What is the What-if Machine (WhIM)?
WhIM is an algorithm developed by EpiVax to modify synthetic peptide sequences to identify potential impurities and assess their immunogenicity risk.
Which peptide drugs will EpiVax focus on in their research?
EpiVax will focus on generic drugs such as teriparatide, exenatide, liraglutide, and tirzepatide.
What is the significance of immunogenicity risk assessment?
Immunogenicity risk assessment helps differentiate between benign and potentially risky drug impurities, ensuring safer drug products for patients.
